Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2024-01-17 00:00:00 ET · period of report 2024-01-12 · accession 0001610717-24-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-01-17 | 2024-01-12+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $4.31 | +75.0K | 690.1K | +12% | +$323.2K |
| DMT | 2024-01-17 | 2024-01-12+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | S - Sale+OE | $40.15 | -75.0K | 677.9K | -10% | -$3.01M |
| DMT | 2024-01-17 | 2024-01-12+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $0.00 | -75.0K | 324.5K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-16 | M | A | 62,739 | $4.31 | 740,626 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-16 | S | D | 62,739 | $40.17 | 677,887 | D | — | — | (F4) This transaction was executed in multiple trades in prices ranging from $40.00 to $40.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2024-01-12 | S | D | 12,261 | $40.04 | 677,887 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $40.00 to $40.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2024-01-12 | M | A | 12,261 | $4.31 | 690,148 | D | — | — | |
| 5 | Derivative | Stock Option (right to buy) | 2024-01-12 | M | D | 12,261 | $0.00 | 387,193 | D | $4.31 · — to 2028-02-26 | 12,261 Common Stock | (F3) The shares subject to the option are fully vested and exercisable. |
| 6 | Derivative | Stock Option (right to buy) | 2024-01-16 | M | D | 62,739 | $0.00 | 324,454 | D | $4.31 · — to 2028-02-26 | 62,739 Common Stock | (F3) The shares subject to the option are fully vested and exercisable. |